initiation of chronic kidney replacement therapy (dialysis or kidney transplantation), and death from kidney disease or death from CV disease. Findings showed treatment with semaglutide reduced ...

Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity or overweight.

"Everyone was randomized to semaglutide or a placebo, all had chronic kidney disease or specific criteria and all had type 2 diabetes," says Dr. Pratley. In addition to taking Ozempic, patients ...

The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.

If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost ...

Medscape Medical News, February 05, 2025 Alert Ozempic Receives New Indications in Chronic Kidney Disease Semaglutide is now approved for reducing the risk for worsening kidney disease and ...

“Chronic kidney disease is a global healthcare problem ... GLP-1 agonists – LEADER with liraglutide and SUSTAIN-6 with semaglutide – in which we included important renal endpoints.

Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...